Lv72
3475 积分 2022-01-07 加入
Safety and efficacy of switching to bictegravir–lenacapavir versus continuing bictegravir–emtricitabine–tenofovir alafenamide in virologically suppressed people with HIV-1 (ARTISTRY-2): a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial
21天前
已完结
Safety and efficacy of switching to bictegravir–lenacapavir versus continuing bictegravir–emtricitabine–tenofovir alafenamide in virologically suppressed people with HIV-1 (ARTISTRY-2): a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial
21天前
已关闭
Safety and efficacy of switching to bictegravir–lenacapavir versus continuing bictegravir–emtricitabine–tenofovir alafenamide in virologically suppressed people with HIV-1 (ARTISTRY-2): a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial
21天前
已关闭
Safety and efficacy of switching to bictegravir–lenacapavir versus continuing bictegravir–emtricitabine–tenofovir alafenamide in virologically suppressed people with HIV-1 (ARTISTRY-2): a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial
21天前
已关闭
The Implications of HIV-1 Subtypes on Pathogenesis, Reservoirs and Cure Strategies
2个月前
已完结
Simple and Effective Purification of Recombinant Peptide Drug, hPTH (1-34), Expressed in E. coli Host
2个月前
已完结
Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1
4个月前
已完结
Guidelines for diagnosis and treatment of syphilis, gonorrhea and genital Chlamydia trachomatis infection （2020）
5个月前
已完结
基于真实世界数据的艾诺米替转换治疗HIV-1感染者144周有效性和安全性研究
8个月前
已关闭
Beware of Resistance to 2nd-generation Integrase Inhibitors: A Systematic Meta-analysis of HIV-1 Integrase Inhibitors Resistance and Drug Resistance Mutations
9个月前
已完结
皖公网安备34019202002308
